Bioalmanac
Thymosin alpha-1
Tα1 · Thymalfasin · Zadaxin (brand)
An immune-modulating peptide approved in more than thirty countries for hepatitis B, and studied in sepsis and as a vaccine adjuvant. Not approved in the United States.
Storage
- Freeze-dried powder
- Refrigerated at 2–8 °C, protected from light.
- After mixing
- Refrigerated at 2–8 °C. Do not freeze once mixed.
- Long-term, frozen
- Unopened powder is stable at −20 °C or colder.
Reconstitution — 10 mg vial, 1600 mcg dose
On a 1 mL U-100 syringe. Check every figure against your own vial before drawing.
| Water added | Concentration | Volume to draw | Units | Doses per vial |
|---|---|---|---|---|
| 1 mL | 10 mg/mL | 0.16 mL | 16 units | 6.3 |
| 2 mL | 5 mg/mL | 0.32 mL | 32 units | 6.3 |
| 3 mL | 3.333 mg/mL | 0.48 mL | 48 units | 6.3 |
| 5 mL | 2 mg/mL | 0.8 mL | 80 units | 6.3 |
Dose ranges reported in sources
Descriptions of what sources report, not recommendations.
| Goal | Range | Frequency | Source |
|---|---|---|---|
| Approved regimen for hepatitis B | 1600 mcg | Twice weekly for six months | Clinical trial |
| Commonly described for general use | 450–1600 mcg | Two or three times weekly | Community practice |
When to stop
- Any new joint pain, rash, or unexplained fever. These can be early signs of immune activation going the wrong way.
- Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.
- A flare of any existing autoimmune condition.
- Signs of infection at an injection site.
Use your browser’s print dialog and choose “Save as PDF”. This block is hidden when printed.